Researchers discovered gallic acid suppresses tumor progression by targeting the NF-κB/KLF7/L1CAM axis in prostate cancer. The study demonstrated that gallic acid significantly impaired aggressive behaviors of PC-3 and LNCaP cells without toxicity to normal cells.
The UVA Weber Symposium will discuss the latest research and advancements in metastasis, a complex area of cancer research and care. The event will bring together top scientists and physicians to present findings on cancer metastasis, genetics, and treatment considerations.
Researchers found that stroke promotes glioma growth and tumor microenvironment remodeling, linking brain injury to malignant brain tumors. The study identified distinct populations of brain cells, including tumor-associated astrocytes, that contribute to the development of glioma.
A new, incisionless liver cancer treatment called histotripsy was associated with low rates of laboratory toxicity and procedural complications in a real-world review of 972 patients. However, the study found that 11% of patients died within 30 days, suggesting that advanced cancer and overall disease burden may be contributing factors.
A new AI tool has been developed to predict treatment and survival outcomes in patients with advanced non-small cell lung cancer treated with immunotherapy. The tool consistently outperformed standard clinical biomarkers, achieving high accuracy scores in predicting survival outcomes.
Research identifies MLKL as a protein that helps drive liver cancer associated with obesity-related fatty liver disease by reducing mitochondrial function, promoting tumor development. Removing MLKL reduces liver tumors but not fatty liver or liver inflammation, suggesting a new therapeutic target for liver cancer treatment
Recent health tech advancements include drone delivery for organ transportation, AI tools in education with potential risks to childhood development, and early cancer neurotechnology research. Consumer wearables are shifting towards data interpretation, with wearable platforms needed to provide meaningful insights from collected data.
Researchers will investigate how mutation rates evolve across species, with potential insights into cancer progression and antibiotic resistance. The study aims to understand how reproductive modes alter mutation rates, which could inform broader understanding of evolution and adaptation.
Recent research found that D-serine accelerates gastric cancer growth by suppressing cytotoxic T-cell activity and promoting immunosuppressive macrophages. High serum D-serine concentrations were linked to ICI therapy resistance in patients, suggesting its potential as a biomarker for disease progression.
Researchers discovered how breast tumors recruit immune cells to attract nerves that support tumor growth and treatment resistance. Blocking nerve growth may boost the immune response to fight cancer.
The Alliance QUANTUM trial is testing whether post-transplant consolidation therapy with teclistamab improves survival in patients with primary plasma cell leukemia. Plasma cell leukemia is a rare but aggressive blood cancer with poor long-term survival rates.
Researchers estimate that relabeling Grade Group 1 prostate cancer as a precancerous condition could reduce unnecessary treatment and prevent nearly 2,400 prostate cancer deaths annually. This change may encourage more men to get screened, potentially leading to fewer deaths from aggressive prostate cancer.
Research in flies shows that tumor cells with chromosomal instability can become senescent and release signals altering neighboring tissue behavior. This process promotes tumor growth by inducing the death of nearby healthy cells.
A multicenter clinical trial found that implanting collagen tiles during brain surgery improved tumor control and lowered the risk of recurrence by 12.1% compared to current standard of care. Patients treated with tile-based radiation therapy (TBRT) had a median overall survival of 42.5 months, more than double the 17.6 months seen wit...
The American Cancer Society has endorsed two new types of stool tests and recommends limiting the use of blood tests for colorectal cancer screening. The guidelines aim to encourage people to get screened while improving detection rates.
Researchers discovered lung cancer cells change identity to resist treatment by reactivating a process involved in early lung development. This could help doctors predict which patients respond well to treatment and provide personalized care.
Researchers from The University of Osaka identified a unique genetic pattern in carcinoma cuniculatum, a rare type of oral cancer with slower growth and lower risk of spread. This discovery may lead to improved diagnosis and targeted treatment for this challenging-to-diagnose condition.
Researchers discover that kinases play a crucial role in moving cholesterol to activate a growth pathway in aggressive cancers. Without these enzymes, cancer cells are blocked from fueling tumor growth. The study highlights the importance of targeting lipid enzymes as a potential treatment strategy for cancers with TP53 mutations.
Dr. Michele Carbone received the 2026 Szent-Görgyi Prize for his groundbreaking discovery that mesothelioma can be transmitted through families in a Mendelian fashion, driven by inherited mutations in the BAP1 gene. His research has transformed how the disease is understood, diagnosed, treated and prevented worldwide.
Researchers have used fungal light-producing enzymes to track processes like tumor progression and inflammatory responses. The study reveals the role of caffeylpyruvate hydrolase (CPH) in breaking down oxyluciferin, allowing for sustainable bioluminescence.
The Alliance A082402 study evaluates the effectiveness of involved-station I²-PORT in reducing NSCLC recurrence without long-term side effects. Participants will undergo randomized treatment with or without targeted radiation therapy after surgery.
Researchers developed RegVelo, an AI framework that models cellular dynamics and gene regulation to predict cellular fate decisions. The model traces developmental trajectories and simulates regulatory interactions, providing insights into hidden drivers of development and potential therapeutic targets.
The ERASur clinical trial is investigating whether total ablative therapy can improve overall survival in patients with newly diagnosed, limited metastatic colorectal cancer. The study has reached one-third patient accrual milestone, signaling strong momentum.
The ASPIRE trial aims to enroll 1,200 participants with advanced prostate cancer and assess the impact of chemotherapy on overall survival and disease progression. Genetic profiling is included to identify patients who benefit most from intensified treatment.
A research team at the University of Cologne discovered that the protein cFLIP can be used to override the defences of Diffuse Large B Cell Lymphoma (DLBCL) against programmed cell death. Targeting cFLIP could re-activate cell death in lymphoma cells and provide a new therapy option.
Researchers have identified the Prrx1 gene as a key regulator of metastatic potential in breast cancer tumors. This discovery helps explain why highly invasive cells do not always give rise to metastases, and how cells combine invasiveness and proliferation to become the most dangerous from a clinical perspective.
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
Chemokines regulate immune cell infiltration and local immunity in tumors, and targeting their receptor axis has emerged as a promising therapeutic target in cancer immunotherapy. Chemokine-modulating strategies combining with other immunotherapies have demonstrated considerable synergistic potential.
A new study maps how rare mixed tumors evolve into hybrid cell states and immune-protected neighborhoods, pointing to new ways to detect and treat combined small-cell lung cancer. The findings reveal that these tumors do not arise from two separate cancers but rather from a single ancestral cell that evolves over time.
A new article in JMIR Publications showcases precision oncology's success, where individualized multi-drug regimens improve treatment responses and survival rates for patients with advanced cancers. The study found that closely matching drug therapies to tumor mutations leads to better outcomes, while also offering a safer profile.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
A recent study found that women have a 21% lower risk of death compared to men, but a 12% higher risk of severe side effects from cancer treatment. The research, conducted in partnership with international collaborators, analyzed data from over 20,000 cancer patients and identified sex-based differences in survival and treatment toxicity.
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
Researchers at the University of Gothenburg have identified a protein, ATF4, linked to increased metastasis and recurrence in lung cancer. The study reveals that older individuals' tumors are smaller and grow more slowly, yet more likely to have spread when detected.
New research reveals that tumor cells in supratentorial ependymomas cluster into distinct neighborhoods, each with a specific role, such as proliferating or invading. Understanding these cell subtypes could help predict treatment response and inform targeted therapies for this aggressive childhood brain cancer.
Severe COVID-19 and influenza infections can prime the lungs for cancer development, according to new research. Vaccination, however, largely prevents these changes, suggesting a reduced risk of lung cancer.
A new clinical study aims to improve communication between patients and families about genetic risks of colorectal cancer. The trial will compare two methods of sharing genetic test results with close relatives, with the goal of learning which approach helps more family members get necessary genetic testing.
A new study shows that pancreatic cancer cells' ability to detect the extracellular matrix determines their growth rate and response to chemotherapy. The researchers found that cells detecting ECM have low autophagy levels and high growth rates, while those farther away from ECM have high autophagy levels and can survive chemotherapy.
A Mass General Brigham-led study found that integrating feedback and personalized palliative care can improve the quality of life for children with advanced cancer. The study showed significant improvements in symptoms and well-being for patients who received the intervention, highlighting the potential benefits of early palliative care.
Researchers found that certain gut bacteria can deplete amino acids, affecting tumor growth or activating immune cells. Tailoring diets and microbiome strategies may enhance anti-tumor activity and support personalized therapy.
A machine-learning-based approach has been developed to map real-time tumor metabolism in brain cancer patients, helping doctors discover effective treatment strategies. The digital twin uses patient data to calculate metabolic flux, predicting which treatments are likely to work for individual cases of glioma.
A new study published in CANCER found that men are more likely to have advanced disease and high myeloma load at diagnosis compared to women. Men were also less likely to have low bone mineral density and had different chromosomal abnormalities, which may contribute to the sex disparity in multiple myeloma risk.
Researchers identified specific microbial patterns associated with tumor location, genetic features, and patient outcomes. A new Microbial Risk Score (MRS) offers a practical way to translate complex microbiome data into prognostic insight.
A recent study published in Gut journal revealed that Streptococcus anginosus produces methionine metabolites, which significantly contribute to the development of gastric cancer. The research opens new paths for microbiota-targeted prevention strategies.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
Researchers discovered a novel mechanism behind small cell lung cancer's aggressiveness, involving the lack of caspase-8, leading to necroptosis and inflammation that fosters tumor progression. This pre-tumoral inflammation suppresses anti-cancer immune responses, promoting metastasis and relapse.
A recent review suggests that Clostridioides difficile infection may promote the development of gastrointestinal tumors, including colorectal cancer. The bacterium's toxins can cause damage to the epithelial cytoskeleton and induce inflammation, leading to chronic colitis and increased risk of CRC.
Researchers at UT Health San Antonio are developing APOBEC inhibitors to block tumor mutation rates and slow cancer's evolution. The goal is to strengthen current therapies and improve their long-term effectiveness.
A blood test may help doctors identify which patients with colon cancer can benefit from anti-inflammatory medication and chemotherapy after surgery. The test measures circulating tumor DNA levels, and high-risk patients who test positive see improved survival rates when taking celecoxib with chemotherapy.
Researchers at MD Anderson have made significant discoveries in the treatment of rare bile duct cancers, with zanidatamab showing promising results. Additionally, a study identified RASH3D19 as a target to overcome treatment resistance in KRAS-mutant cancers.
A specific protein, RASH3D19, activates the RAS signaling pathway involved in aggressive tumor growth and resistance to KRAS inhibitors. Blocking RASH3D19 improves outcomes in preclinical models, suggesting a potential therapeutic strategy.
A microRNA cocktail has been developed to weaken glioblastoma, a type of aggressive brain tumor. The formulation, comprising 11 different non-coding RNAs, slows the growth of cancer cells and enhances chemotherapeutic drug activity.
Researchers identified a targeted drug that blocks a specific genetic pathway to reverse tumor-driving cellular interactions, potentially restoring DNA function and benefiting patients with synovial sarcoma. The study's findings endorse a promising strategy to improve outcomes for this rare but deadly cancer.
Researchers at UC Riverside and City of Hope have developed a novel Pin1 degrading compound that suppresses pancreatic cancer peritoneal metastases. The treatment targets not only cancer cells but also tumor-supporting cells, potentially overcoming treatment resistance.
A liquid biopsy test may enable early detection of various cancers, increasing stage I–III diagnoses by 10-30% and stage IV diagnoses by 45%. This could improve patient outcomes and reduce the economic impact of cancer. The study's findings suggest a game-changing approach to cancer control.
Researchers at Sanford Burnham Prebys Medical Discovery Institute found that aging accelerates pancreatic cancer progression, leading to faster tumor growth and metastasis. By understanding the impact of age on the tumor microenvironment, they developed a new approach to treating this disease in frail patients.
A study published in Molecular Cancer suggests that blocking the thyroid hormone receptor Beta, TRβ, can inhibit the growth of prostate cancer cells. This discovery may lead to a new way of treating certain types of aggressive prostate cancer.
A new Alliance trial is exploring the effectiveness of a combination of targeted therapy and immunotherapy for patients with advanced adrenocortical carcinoma, a rare and aggressive cancer. The study aims to improve disease control and quality of life for patients with limited treatment options.
BH3 mimetics demonstrate potent anti-cancer activity by targeting pro-survival BCL-2 proteins, effectively eradicating leukaemia cells with complex mutations. The review highlights several important findings about BH3 mimetics and their role in treating acute myeloid leukaemia.
Researchers discovered a mutation in the POT1 gene that prevents telomeres from repairing, leading to pulmonary fibrosis. This study highlights the importance of personalising treatments for diseases caused by dysfunctional telomeres.